ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0430

The Reference Interval and Risk Factors of NT-ProBNP in CKD Patients Without Heart Failure

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Chen, Junzhe, Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, Guangdong, China
  • Tang, Ying, Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, Guangdong, China
  • Xu, Zhenjian, Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, Guangdong, China
  • Huang, Qiuyan, Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, Guangdong, China
  • Xu, Anping, Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, Guangdong, China
Background

N-terminal pro-B-type natriuretic peptide (NT-proBNP), a diagnostic marker of heart failure (HF), as well as the specific and sensitive biomarker of HF is been demonstrated to be affected by renal function. NT-proBNP is significantly associated with the severity of GFR loss. However, the reference interval (RI) of NT-proBNP in non-dialysis chronic kidney disease (CKD) patients without HF remains unclear. The aim of our study was to establish the threshold value of NT-proBNP which could help to early recognition, prevention and treatment for HF.

Methods

All patients diagnosed with CKD aged more than 18 years old in our hospital from Jan 01, 2014 to Dec 31, 2019 were recruited into this study. Individuals who diagnosed with HF were excluded. The RI for NT-proBNP was defined by nonparametric method and risk factors were analyzed by linear regression analysis.

Results

A total of 1260 CKD patients without HF were included in this study. Of them, 588(46.67%) were female. NT-proBNP were increased with the advanced stage of kidney function in CKD patients without HF. The median level of NT-proBNP in CKD stage 5 ND (non-dialysis) patients without HF were the highest, as 610.25 pg/ml. The RIs for NT-proBNP in CKD patients without HF with respect to kidney function stage (ranges of stage 1, stage 2, stage 3, stage 4, stage 5 ND) were 8.15-536.32, 12.38-811.90, 16.62-1411.05, 33.14-2945.05, 88.58-5533.73pg/ml. We also demonstrated that NT-proBNP was significantly correlated with the serum levels of Hb (β=-0.174, P<0.001), Ca (β=-0.214, P<0.001), P (β=0.111, P<0.001), hs-CRP (β=0.140, P<0.001), and eGFR(β=-0.243, P<0.001).

Conclusion

Our study proved that NT-proBNP was increased with the advanced stage of GFR in CKD patients without HF. The RI of NT-proBNP varied among the different stages of CKD without HF and multiple factors contributed to NT-proBNP, which could help clinicians to prevent and take actions against the occurrence of HF.

Funding

  • Government Support - Non-U.S.